Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2a study of OPT-302 plus aflibercept for persistent center-involved diabetic macular edema
MOH_2018-10-04_003675Phase 2Active, not recruiting
- Sponsor
- Opthea Limited
- Start
- Sep 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sozinibercept and aflibercept in diabetic macular edema (DME) (5 arms), sponsored by Opthea Limited. Primary endpoint: Safety and tolerability. Started Sep 2018; status: active, not recruiting.
02
Drugs
soziniberceptaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2018-10-04_003675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-04_003675.